Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study

OBJECTIVE: After surgery, when somatostatin analogs (SAs) do not normalise IGF-I, pegvisomant (PEG) is indicated. Our aim was to define the medical reasons for the treatment of patients with PEG as monotherapy (M) or combined with SA, either as primary bitherapy, PB (PEG is secondarily introduced af...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Endocrine
Main Authors: Kuhn, Emmanuelle, Caron, Philippe, Delemer, Brigitte, Raingeard, Isabelle, Lefebvre, Hervé, Raverot, Gérald, Cortet-Rudelli, Christine, Desailloud, Rachel, Geffroy, Clementine, Henocque, Robin, Brault, Yves, Brue, Thierry, Chanson, Philippe
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2020
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7835180/
https://ncbi.nlm.nih.gov/pubmed/32986202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12020-020-02501-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker